Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.


Onal C., Kose F., Ozyigit G., Aksoy S., Oymak E., Muallaoglu S., ...Daha Fazla

The Prostate, cilt.81, ss.543-552, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 81
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1002/pros.24132
  • Dergi Adı: The Prostate
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, Gender Studies Database, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.543-552
  • Anahtar Kelimeler: abiraterone, enzalutamide, oligometastasis, prostate cancer, stereotactic radiotherapy, MITOXANTRONE PLUS PREDNISONE, ABIRATERONE ACETATE, INCREASED SURVIVAL, RADIATION-THERAPY, DOUBLE-BLIND, ENZALUTAMIDE, DOCETAXEL, PROGRESSION, CHEMOTHERAPY, DECLINE
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background Metastasis-directed therapy (MDT) utilizing stereotactic body radiotherapy (SBRT) for oligoprogressive lesions could provide a delay in next-line systemic treatment (NEST) change while undergoing androgen receptor-targeted agents (ARTA) treatment. We evaluated prognostic factors for prostate cancer-specific survival (PCSS) and progression-free survival (PFS) to characterize patients receiving treatment with ARTA who may benefit from MDT for oligoprogressive lesions. The impact of MDT on delaying NEST and the predictive factors for NEST-free survival (NEST-FS) were also assessed.